Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAnesthesiologyPremera Bluecross IV anesthetic coverage update | …
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy 5.01.586

    Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric or Substance Use Disorders

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.586 alerts

    Get alerted when Policy 5.01.586 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage stance for intravenous infusion of anesthetic agents (including ketamine and lidocaine) for chronic pain syndromes and psychiatric/substance use disorders, and describes associated coding and evidence considerations for providers.

    Policy Summary
    PayerPremera Bluecross
    PolicyIntravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric or Substance Use Disorders
    Policy CodePolicy 5.01.586
    Change TypeClarified investigational designationcoding removal
    Effective DateJul 1, 2026
    Last ReviewJun 9, 2026
    Next Review DateJul 1, 2026
    Key ActionWhen billing for IV anesthetic infusions, use the listed CPT/HCPCS codes and verify member benefits; note these uses are classified investigational and may be denied.
    SourceLink
    POLICY UPDATE CHANGES

    IV ketamine is considered investigational in any setting or in conjunction with any other service, not just when it is either monotherapy or in conjunction with psychotherapy.

    In addition to IV ketamine, any office visits, clinic visits, psychotherapy sessions, evaluation and management sessions, or any other sessions during which IV ketamine is administered are also considered investigational.

    HCPCS code J2001 was removed from the policy (termed October 1, 2024).

    InvestigationalIV ketamine coverage stance
    Investigational

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    IV lidocaine coverage stance
    100+ClinicalTrials.gov trials
    Short-termEvidence duration
    NoMedicare NCD

    Coverage Criteria and Rationale

    Investigational — Intravenous anesthetic infusions

    Covered when ALL of the following are met

    Investigational stance: Intravenous infusion of ketamine for treatment of depression, anxiety, other psychiatric symptoms or disorders, substance use disorders, and/or chronic pain is considered investigational, including in any setting or in conjunction with any other service (this includes ketamine-assisted psychotherapy).

    Services are categorized as investigational irrespective of setting or concurrent services.

    Associated encounters: Any office visits, clinic visits, psychotherapy sessions, evaluation and management sessions, or any other sessions during which there is intravenous infusion of ketamine are considered investigational.

    Related encounters during administration inherit investigational status.

    Other IV anesthetics: Intravenous infusion of any other anesthetics (e.g., lidocaine) for the treatment of chronic pain, including but not limited to chronic neuropathic pain, chronic daily headache, and fibromyalgia, is considered investigational.

    Applies to lidocaine and other IV anesthetics for listed chronic pain conditions.

    Coverage rationale (Investigational / insufficient evidence)

    Policy stance and evidence summary informing coverage:

    Policy Coverage Stance: IV ketamine is considered investigational for the treatment of psychiatric disorders and substance use disorders in any setting and in conjunction with any other service; related visits or sessions during which IV ketamine is administered are also investigational.

    From policy history clarifications

    Evidence summary — psychiatric indications: Randomized trials and case series report short-term symptom improvements in OCD and PTSD with IV ketamine, but trials are limited by small sample sizes, potential unblinding or carryover effects, adverse events, and short durability of benefit; the evidence is insufficient to demonstrate an overall net health benefit.

    From summary of evidence

    Regulatory context: IV lidocaine and IV ketamine for chronic pain or psychiatric disorders are off-label uses: ketamine is FDA-approved for anesthesia/diagnostic procedures and lidocaine for arrhythmias and local anesthesia; neither is approved by the FDA for chronic pain or psychiatric indications described here.

    From regulatory status

    This policy does not address continuous subcutaneous or IV infusion of anesthetics for managing chronic pain conditions such as terminal cancer pain. The document distinguishes episodic subanesthetic IV courses (e.g., test infusions or short courses of lidocaine or ketamine used in treatment planning or research for chronic neuropathic pain) from continuous infusions intended for long‑term symptom control, which are outside the scope of this policy. (See definitions of chronic daily headache, neuropathic pain, and related clinical context.)

    This policy does not apply to Medicare Advantage determinations and notes that IV ketamine and IV lidocaine for chronic pain or psychiatric disorders are off‑label uses per FDA approvals. The policy further clarifies operational and coverage implications in its history and regulatory sections, including changes to investigational designations and code listings. Providers should verify member benefit plan limits and prior‑authorization requirements with the member’s plan.

    The available evidence is insufficient to conclude that IV anesthetic infusions (including ketamine and lidocaine) for chronic pain syndromes or treatment‑resistant psychiatric disorders improve net health outcomes. Randomized trials and systematic reviews report short‑term symptom improvements in some settings (for example, temporary relief for some chronic pain patients or transient depression benefit lasting days to a few weeks), but limitations such as small sample sizes, lack of active controls, possible unblinding, carryover effects, short durability of benefit, and treatment‑related adverse events raise concerns about net benefit. Additional well‑designed clinical trials evaluating long‑term efficacy and safety are needed.

    The policy explicitly states that IV ketamine in any setting or in conjunction with any other service is considered investigational. This designation was clarified to apply regardless of whether ketamine is provided as monotherapy, as part of ketamine‑assisted psychotherapy, or during any office, clinic, psychotherapy, evaluation and management, or other session in which IV ketamine is administered; such services are therefore subject to investigational exclusion and may be denied.

    Billing and Code Lists

    Listed procedure/HCPCS/CPT/administration codesmixed
    0820TContinuous in-person monitoring and intervention (e.g., psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; first physician or other qualified health care professional, each hour.
    0821TContinuous in-person monitoring and intervention (e.g., psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; second physician or other qualified health care professional, concurrent with first physician or other qualified health care professional, each hour (List separately in addition to code for primary procedure).
    0822TContinuous in-person monitoring and intervention (e.g., psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; clinical staff under
    96365Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour.
    96366Each additional hour (list separately in addition to code for primary procedure).
    96374Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance/drug.
    J3490Unclassified drugs.
    Previously listed HCPCS code removedHCPCS
    J2001Removed/termed October 1, 2024
    CPT codes added in prior update (listed in history)CPT
    0820TNew CPT code added previously (policy history notes addition)
    0821TNew CPT code added previously (policy history notes addition)
    0822TNew CPT code added previously (policy history notes addition)

    Provider Billing, Authorization, and Documentation

    Billing Rule

    Billing codes for IV anesthetic infusion services

    Use the listed CPT and HCPCS codes when billing for IV anesthetic infusion services and related continuous monitoring/psychotherapy: 0820T, 0821T, 0822T, 96365, 96366, 96374, and J3490 (unclassified drugs). Note that HCPCS code J2001 was removed (termed Oct 1, 2024).

    • 0820T — Continuous in‑person monitoring/intervention, first physician/qualified health professional, per hour.
    • 0821T — Continuous in‑person monitoring/intervention, second physician/qualified health professional (concurrent), per hour.
    • 0822T — Continuous in‑person monitoring/intervention, clinical staff (description truncated in source).
    • 96365 — Intravenous infusion, initial, up to 1 hour.
    • 96366 — Each additional hour (list separately).
    • 96374 — Therapeutic/prophylactic/diagnostic injection; IV push, single or initial substance/drug.
    • J3490 — Unclassified drugs.
    • J2001 — Previously listed HCPCS code removed (termed October 1, 2024).

    Background and Evidence Summary

    Intravenous ketamine and lidocaine have been studied for chronic neuropathic pain, chronic daily headache, fibromyalgia, and treatment‑resistant psychiatric disorders (including major depressive disorder, OCD, and PTSD). Protocols commonly involve subanesthetic infusions delivered over hours, sometimes as a series of repeated infusions. Trials report transient symptom improvements in some patients but are limited by small sample sizes, inconsistent controls, short durability of effect, and a risk of adverse events such as headache, anxiety, dissociation, nausea, and dizziness. Regulatory status notes that IV ketamine and IV lidocaine for these indications are off‑label. Given these factors, the policy classifies IV lidocaine and IV ketamine infusions for the listed chronic pain and psychiatric/substance use disorder indications as investigational.

    Clinical Definitions

    Chronic daily headache definition
    DefinitionChronic daily headache: a headache disorder that occurs 15 or more days a month for at least three months and includes chronic migraine, new daily persistent headache, hemicranias continua, and chronic tension-type headache.
    Duration criterionOccurs ≥15 days per month for at least 3 months.
    Included subtypesIncludes chronic migraine, new daily persistent headache, hemicranias continua, and chronic tension-type headache.
    Exclusions noted in policyThis policy does not address continuous subcutaneous or continuous IV infusion of anesthetics for terminal cancer pain or similar palliative continuous infusions.
    Neuropathic pain definition
    DefinitionNeuropathic pain: pain often disproportionate to the triggering injury characterized by thermal or mechanical allodynia, dysesthesia, and/or hyperalgesia; symptoms may persist ≥6 months and involve peripheral and central sensitization.
    Policy Summary
    PayerPremera Bluecross
    PolicyIntravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric or Substance Use Disorders
    Policy CodePolicy 5.01.586
    Change TypeClarified investigational designationcoding removal
    Effective DateJul 1, 2026
    Last ReviewJun 9, 2026
    Next Review DateJul 1, 2026
    Key ActionWhen billing for IV anesthetic infusions, use the listed CPT/HCPCS codes and verify member benefits; note these uses are classified investigational and may be denied.
    SourceLink
    On This Page
    Coverage Criteria and RationaleBilling and Code ListsProvider Billing, Authorization, and DocumentationBackground and Evidence SummaryClinical Definitions
    Prior Authorization

    Confirm benefits and prior authorization requirements

    Verify member benefits and prior authorization requirements before scheduling IV anesthetic infusion services; coverage determinations are subject to the limits and conditions of the member's benefit plan and may require prior authorization per the plan.

    • Consult the member benefit booklet or contact member services to determine applicable benefit limitations.
    • Prior authorization may be required by the member's plan (policy does not specify plan-level PA rules).
    Step Therapy

    Step‑therapy context — informational

    This policy describes typical clinical treatment pathways (e.g., fibromyalgia treatments such as pregabalin, non‑narcotic analgesics, or low‑dose antidepressants) and states that IV anesthetic infusions are considered an investigational approach rather than an established step in therapy; no formal step‑therapy algorithm or mandatory sequencing is specified.

    • Fibromyalgia is typically treated with neuropathic pain medications such as pregabalin, non‑narcotic pain relievers, or low doses of antidepressants.
    • The policy does not establish a required step‑therapy pathway for IV anesthetic infusions.
    Note
    Documentation Required

    Coding and documentation guidance for billing

    Include documentation of the IV infusion and associated monitoring or psychotherapy services and bill using the appropriate CPT/HCPCS codes listed in the policy; however, the policy classifies these uses as investigational and not supported for the covered indications.

    • Document the IV anesthetic agent administered, infusion duration, and clinical justification.
    • Bill continuous monitoring/psychotherapy hours with 0820T/0821T/0822T and infusion time with 96365/96366; use J3490 for unclassified drugs when appropriate.
    Prior Authorization

    Benefit verification required

    Before providing services, verify that the member’s plan covers the service and any limitations; consult the member benefit booklet or contact customer service to determine coverage for a specific member.

    • Coverage is subject to the limits and conditions of the member benefit plan.
    • Contact member services or review the benefit booklet to confirm coverage and prior authorization requirements.
    Denial Risk

    Services considered investigational — potential grounds for denial

    IV infusion of ketamine (for depression, anxiety, other psychiatric disorders, substance use disorders, and/or chronic pain) and IV infusion of other anesthetics (e.g., lidocaine) for chronic pain are designated investigational and therefore are subject to denial.

    • Investigational status applies irrespective of setting or whether administered in conjunction with other services (includes ketamine‑assisted psychotherapy).
    • Related office visits, clinic visits, psychotherapy sessions, evaluation and management sessions, or any sessions during which IV ketamine is administered are also considered investigational.
    Denial Risk

    Investigational designation creates denial risk for IV ketamine services

    Because the policy designates IV ketamine (and associated sessions during which IV ketamine is administered) as investigational in any setting, submitting claims or requests for authorization for these services creates a denial risk under this policy.

    • The July 1, 2026 policy clarification explicitly states IV ketamine is investigational in any setting or in conjunction with any other service.
    • Operational clarification: related encounters during administration inherit investigational status and may be denied.
    Key featuresAllodynia (pain from normally nonpainful stimuli), dysesthesia (constant unpleasant/electrical sensation), and hyperalgesia (exaggerated response to painful stimuli).
    Typical durationSymptoms may continue longer (e.g., ≥6 months) than clinically expected after an illness or injury.
    Pathophysiology noteThought to involve peripheral afferent sensitization, neurogenic inflammation, sympathetic afferent coupling, and central sensitization mediated in part via NMDA receptors.
    Fibromyalgia definition
    DefinitionFibromyalgia: a chronic state of widespread pain and tenderness, generally considered a disorder of central pain processing or central sensitization, with focal areas of hyperalgesia (tender points).
    Associated findingsBiochemical alterations may include NMDA receptor changes, low serotonin, suppressed dopamine release in the limbic system, HPA-axis dysfunction, and elevated substance P.
    Typical treatmentsTypically treated with neuropathic pain medications (e.g., pregabalin), non-narcotic analgesics, or low-dose antidepressants.
    Off-label use definition
    DefinitionOff‑label use: use of an FDA‑approved drug for indications not specified in the FDA approval; in this policy, IV ketamine and IV lidocaine for chronic pain or psychiatric disorders are off‑label uses.
    Regulatory examplesIV lidocaine is FDA‑approved for arrhythmias and local anesthesia but IV lidocaine for chronic pain or psychiatric disorders is off‑label; ketamine hydrochloride injection is approved for diagnostic and surgical anesthesia but IV ketamine for chronic pain or psychiatric disorders is off‑label.
    Policy implicationOff‑label designation is one factor in the policy’s assessment; IV ketamine and IV lidocaine for the covered chronic pain and psychiatric indications are described as off‑label and are considered investigational under this policy.